<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02919371</url>
  </required_header>
  <id_info>
    <org_study_id>2141-102</org_study_id>
    <nct_id>NCT02919371</nct_id>
  </id_info>
  <brief_title>Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)</brief_title>
  <official_title>Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Faisal Specialist Hospital &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Faisal Specialist Hospital &amp; Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combined sunitinib and bevacizumab in advanced renal cell carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II trial of combined sunitinib and bevacizumab in advanced renal cell
      carcinoma ( CASBA) where Bevacizumab will be used only on day 29 of each 6 weeks sunitinib
      cycle.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bevacizumab maximum tolerated dose, in combination with sunitinib</measure>
    <time_frame>12 weeks from enrolling patient # 6</time_frame>
    <description>This is the phase I part of the study. patient will enroll on Bevacizumab dose of 5 mg/kg body weight. If no dose limiting toxicity in 1st 6 patients, the dose will be escalated to 10 mg/kg in the remainder of the patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess response rate to the combination of sunitinib and bevacizumab</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>response rate is the combination of partial response and complete response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the progression free survival on the combination of sunitinib and bevacizumab</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Progression free survival will be calculated from time of starting therapy till progression or death whichever comes first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival of patients in this regimen</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, up to 5 years</time_frame>
    <description>Overall survival will be calculated from date of start on therapy till death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment related-adverse effects as assessed by CTCAE v 4.03</measure>
    <time_frame>up to 5 years</time_frame>
    <description>toxicity will be graded according to the NCI-CTC version 4.03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sunitinib and Bevacizumab Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell carcinoma (CASA)Combined Alternating Sunitinib and Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days</description>
    <arm_group_label>Sunitinib and Bevacizumab Arm</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle</description>
    <arm_group_label>Sunitinib and Bevacizumab Arm</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed renal cell carcinoma with clear cell histology ( mixed
             histology with clear cell component is accepted)

          2. Patient should have either locally advanced or metastatic disease

          3. No prior anti-cancer therapy

          4. Age ≥ 18 years

          5. Life expectancy of 3 months or more

          6. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
             version 1.1

          7. Performance status 0-2 by ECOG scale

          8. Patients with controlled brain metastasis are accepted

          9. Adequate renal function: serum creatinine ≤ 2 times the institutional upper limit of
             normal

         10. Adequate hepatic function: total bilirubin within normal institutional limits, serum
             AST and ALT levels ≤2 times the institutional upper limit of normal or ≤ 5 times the
             institutional upper limit of normal of elevated because of liver involvement

         11. Coagulation (PT ≤ 1.5 times the institutional upper limit of normal)

         12. Adequate hematological values: leukocyte count ≥3.0 x 109/L, an absolute neutrophil
             count ≥1.5 x 109/L, a platelet count ≥100 x 109/L and hemoglobin ≥ 9.0 g/dL

         13. Urine dipstick for proteinuria &lt;1+, patients discovered to have ≥ 1+ on dipstick
             urinanalysis at baseline should have urine protein/urine creatinine ratio ≤1

         14. Singed written informed consent before enrolment

         15. Patient should have unresectable disease ( for both the primary tumor and the
             metastasis)

        Exclusion Criteria:

          1. Inability to comply with the protocol therapy

          2. Uncontrolled hypertension defined as BP more than 160 systolic and or more than 100
             diastolic despite adequate treatment at the time of treatment initiation.

          3. Severe cardiovascular disease (congestive heart failure NYHA III or IV, unstable
             angina pectoris, myocardial infarction, significant arrhythmias or Transient ischemic
             attack (TIA) or cerebrovascular accident (CVA) in the last 6 months

          4. Major bleeding disorder, significant traumatic injury or recent major surgery within
             28 days of starting therapy. Or minor surgery (FNA/Core biopsy) within 7 days of
             starting therapy

          5. History of abdominal abdominal fistula, gastrointestinal perforation, or
             intra-abdominal abscess within 6 months

          6. Pre-existing thyroid abnormality

          7. Concurrent proarrhythmic medications including terfenadine, quinidine, procainamide,
             disopyramide, sotalol, bepridil, haloperidol, risperidone, indapamide and flecainide

          8. Recent significant hemoptysis (1/2 tea spoon red blood within last month)

          9. Concurrent medication that either CYP 450 3A4 inducers or inhibitors

         10. Concurrent use of proarrhythmic medications including terfenadine, quinidine,
             procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone,
             indapamide and flecainide

         11. Pregnancy or breast feeding, or patient refusal to use appropriate contraception for
             female patients in childbirth age

         12. Previous malignancy within 5 years, except adequately treated non melanomatous skin
             cancer or in situ cervical cancer

         13. Psychiatric or mental disorder, precluding understanding of the information of the
             trial related topics and giving valid informed consent

         14. Any psychological, familial, geographic or social circumstances which could impair the
             patient ability to participate in the trial and comply with follow up.

         15. Any circumstance which might impair the patient's ability to comply with an
             out-patient regimen

         16. Active uncontrolled infection

         17. Serious underlying medical condition (in the judgment of the investigator) which could
             impair the ability of the patient to participate in the trial

         18. Treatment with other experimental drugs within 30 days of entry into the trial

         19. Treatment with other anti-cancer therapy

         20. Legal incapacity

         21. Significant proteinuria (urine protein: creatinine ratio &gt; 1.0)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shouki Bazarbashi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Faisal Specialist Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shouki Bazarbashi, MD</last_name>
    <phone>00966 11 442 3935</phone>
    <email>bazarbashi@kfshrc.edu.sa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fazal Hussain, MD</last_name>
    <phone>966-11-4423949</phone>
    <email>fhussain@kfshrc.edu.sa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Centre, King Faisal Specialist Hospital and Research Centre</name>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shouki Bazarbashi, MD</last_name>
      <phone>00966 11 442 3935</phone>
      <email>bazarbashi@kfshrc.edu.sa</email>
    </contact>
    <contact_backup>
      <last_name>Fazal Hussain, MD</last_name>
      <phone>966-11-4423949</phone>
      <email>fhussain@kfshrc.edu.sa</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2016</study_first_posted>
  <last_update_submitted>October 29, 2017</last_update_submitted>
  <last_update_submitted_qc>October 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No- unless the data are so encouraging then this can be done</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

